{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T22:39:34Z","timestamp":1776379174281,"version":"3.51.2"},"reference-count":42,"publisher":"American Diabetes Association","issue":"2","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"vor","delay-in-days":83,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["098395\/Z\/12\/Z"],"award-info":[{"award-number":["098395\/Z\/12\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["16\/0005407"],"award-info":[{"award-number":["16\/0005407"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","award":["105636\/Z\/14\/Z"],"award-info":[{"award-number":["105636\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Central nervous system (CNS) features in children with permanent neonatal diabetes (PNDM) due to KCNJ11 mutations have a major impact on affected families. Sulfonylurea therapy achieves outstanding metabolic control but only partial improvement in CNS features. The effects of KCNJ11 mutations on the adult brain and their functional impact are not well understood. We aimed to characterize the CNS features in adults with KCNJ11 PNDM compared with adults with INS PNDM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Adults with PNDM due to KCNJ11 mutations (n = 8) or INS mutations (n = 4) underwent a neurological examination and completed standardized neuropsychological tests\/questionnaires about development\/behavior. Four individuals in each group underwent a brain MRI scan. Test scores were converted to Z scores using normative data, and outcomes were compared between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>In individuals with KCNJ11 mutations, neurological examination was abnormal in seven of eight; predominant features were subtle deficits in coordination\/motor sequencing. All had delayed developmental milestones and\/or required learning support\/special schooling. Half had features and\/or a clinical diagnosis of autism spectrum disorder. KCNJ11 mutations were also associated with impaired attention, working memory, and perceptual reasoning and reduced intelligence quotient (IQ) (median IQ KCNJ11 vs. INS mutations 76 vs. 111, respectively; P = 0.02). However, no structural brain abnormalities were noted on MRI. The severity of these features was related to the specific mutation, and they were absent in individuals with INS mutations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>KCNJ11 PNDM is associated with specific CNS features that are not due to long-standing diabetes, persist into adulthood despite sulfonylurea therapy, and represent the major burden from KCNJ11 mutations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc18-1060","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T20:49:21Z","timestamp":1540932561000},"page":"215-224","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":32,"title":["Cognitive, Neurological, and Behavioral Features in Adults With <i>KCNJ11<\/i> Neonatal Diabetes"],"prefix":"10.2337","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-7700","authenticated-orcid":false,"given":"Pamela","family":"Bowman","sequence":"first","affiliation":[{"name":"University of Exeter Medical School, Exeter, U.K."},{"name":"Exeter National Institute for Health Research Clinical Research Facility, Exeter, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Day","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, Exeter, U.K."},{"name":"Exeter National Institute for Health Research Clinical Research Facility, Exeter, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna","family":"Torrens","sequence":"additional","affiliation":[{"name":"Kent Neuropsychology Service, Kent and Medway NHS and Social Care Partnership Trust, Gillingham, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maggie H.","family":"Shepherd","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, Exeter, U.K."},{"name":"Exeter National Institute for Health Research Clinical Research Facility, Exeter, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget A.","family":"Knight","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, Exeter, U.K."},{"name":"Exeter National Institute for Health Research Clinical Research Facility, Exeter, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamsin J.","family":"Ford","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, Exeter, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Flanagan","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, Exeter, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Chakera","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, Exeter, U.K."},{"name":"Exeter National Institute for Health Research Clinical Research Facility, Exeter, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5620-473X","authenticated-orcid":false,"given":"Andrew T.","family":"Hattersley","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, Exeter, U.K."},{"name":"Exeter National Institute for Health Research Clinical Research Facility, Exeter, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Zeman","sequence":"additional","affiliation":[{"name":"University of Exeter Medical School, Exeter, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1167","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"key":"2022031221304967600_B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)60098-8","article-title":"The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study","volume":"386","author":"De Franco","year":"2015","journal-title":"Lancet"},{"key":"2022031221304967600_B2","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa032922","article-title":"Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes","volume":"350","author":"Gloyn","year":"2004","journal-title":"N Engl J Med"},{"key":"2022031221304967600_B3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJMoa061759","article-title":"Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations","volume":"355","author":"Pearson","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031221304967600_B4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/edn.60","article-title":"Transforming lives: transferring patients with neonatal diabetes from insulin to sulphonylureas","volume":"3","year":"2006","journal-title":"European Diabetes Nursing"},{"key":"2022031221304967600_B5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/09687680110047373","article-title":"Molecular physiology of neuronal K-ATP channels (review)","volume":"18","author":"Liss","year":"2001","journal-title":"Mol Membr Biol"},{"key":"2022031221304967600_B6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0165-6147(00)01861-7","article-title":"A role for neuronal K(ATP) channels in metabolic control of the seizure gate","volume":"22","author":"Liss","year":"2001","journal-title":"Trends Pharmacol Sci"},{"key":"2022031221304967600_B7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1126\/science.1186146","article-title":"Muscle dysfunction caused by a KATP channel mutation in neonatal diabetes is neuronal in origin","volume":"329","author":"Clark","year":"2010","journal-title":"Science"},{"key":"2022031221304967600_B8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0014-5793(96)01438-X","article-title":"Overlapping distribution of K(ATP) channel-forming Kir6.2 subunit and the sulfonylurea receptor SUR1 in rodent brain","volume":"401","author":"Karschin","year":"1997","journal-title":"FEBS Lett"},{"key":"2022031221304967600_B9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1055\/s-2002-36759","article-title":"The history of the development of the cerebellar examination","volume":"22","author":"Fine","year":"2002","journal-title":"Semin Neurol"},{"key":"2022031221304967600_B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-418700-9.00001-0","article-title":"Autism spectrum disorder and the cerebellum","volume":"113","author":"Becker","year":"2013","journal-title":"Int Rev Neurobiol"},{"key":"2022031221304967600_B11","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/brain\/121.4.561","article-title":"The cerebellar cognitive affective syndrome","volume":"121","author":"Schmahmann","year":"1998","journal-title":"Brain"},{"key":"2022031221304967600_B12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-8587(13)70059-7","article-title":"Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: a prospective cohort study","volume":"1","author":"Busiah","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031221304967600_B13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1111\/dme.13159","article-title":"Patients with KCNJ11-related diabetes frequently have neuropsychological impairments compared with sibling controls","volume":"33","author":"Carmody","year":"2016","journal-title":"Diabet Med"},{"key":"2022031221304967600_B14","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/dme.13375","article-title":"Neuropsychological impairments in children with KCNJ11 neonatal diabetes","volume":"34","author":"Bowman","year":"2017","journal-title":"Diabet Med"},{"key":"2022031221304967600_B15","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1007\/s00125-006-0246-z","article-title":"Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype","volume":"49","author":"Flanagan","year":"2006","journal-title":"Diabetologia"},{"key":"2022031221304967600_B16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/dme.13135","article-title":"Psychiatric morbidity in children with KCNJ11 neonatal diabetes","volume":"33","author":"Bowman","year":"2016","journal-title":"Diabet Med"},{"key":"2022031221304967600_B17","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc11-2225","article-title":"Visuomotor performance in KCNJ11-related neonatal diabetes is impaired in children with DEND-associated mutations and may be improved by early treatment with sulfonylureas","volume":"35","author":"Shah","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031221304967600_B18","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/pedi.12428","article-title":"ADHD, learning difficulties and sleep disturbances associated with KCNJ11-related neonatal diabetes","volume":"18","author":"Landmeier","year":"2017","journal-title":"Pediatr Diabetes"},{"key":"2022031221304967600_B19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00424-006-0112-3","article-title":"Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes","volume":"453","author":"Girard","year":"2006","journal-title":"Pflugers Arch"},{"key":"2022031221304967600_B20","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1093\/hmg\/ddi305","article-title":"Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP","volume":"14","author":"Proks","year":"2005","journal-title":"Hum Mol Genet"},{"key":"2022031221304967600_B21","doi-asserted-by":"crossref","first-page":"17539","DOI":"10.1073\/pnas.0404756101","article-title":"Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features","volume":"101","author":"Proks","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031221304967600_B22","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.2337\/diabetes.54.9.2645","article-title":"ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes: implications for pharmacogenomic therapy","volume":"54","author":"Koster","year":"2005","journal-title":"Diabetes"},{"key":"2022031221304967600_B23","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2337\/dc15-0837","article-title":"Sulfonylurea therapy benefits neurological and psychomotor functions in patients with neonatal diabetes owing to potassium channel mutations","volume":"38","author":"Beltrand","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031221304967600_B24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/ncpneuro0640","article-title":"Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11","volume":"3","author":"Mlynarski","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"2022031221304967600_B25","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1007\/s00125-006-0407-0","article-title":"Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene","volume":"49","author":"Slingerland","year":"2006","journal-title":"Diabetologia"},{"key":"2022031221304967600_B26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1464-5491.2007.02373.x","article-title":"Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation","volume":"25","author":"Slingerland","year":"2008","journal-title":"Diabet Med"},{"key":"2022031221304967600_B27","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.2337\/dc12-2166","article-title":"Switching to sulphonylureas in children with iDEND syndrome caused by KCNJ11 mutations results in improved cerebellar perfusion","volume":"36","author":"Fendler","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031221304967600_B28","doi-asserted-by":"crossref","first-page":"e0134476","DOI":"10.1371\/journal.pone.0134476","article-title":"Systemic administration of glibenclamide fails to achieve therapeutic levels in the brain and cerebrospinal fluid of rodents","volume":"10","author":"Lahmann","year":"2015","journal-title":"PLoS One"},{"key":"2022031221304967600_B29","unstructured":"Diabetes Genes. Effects of sulphonylurea on the brain [Internet]. Available from https:\/\/www.diabetesgenes.org\/about-neonatal-diabetes\/effects-of-sulphonylurea-on-the-brain\/. Accessed 1 March 2018"},{"key":"2022031221304967600_B30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/13154","article-title":"In vivo evidence for post-adolescent brain maturation in frontal and striatal regions","volume":"2","author":"Sowell","year":"1999","journal-title":"Nat Neurosci"},{"key":"2022031221304967600_B31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jadohealth.2009.05.016","article-title":"Adolescent maturity and the brain: the promise and pitfalls of neuroscience research in adolescent health policy","volume":"45","author":"Johnson","year":"2009","journal-title":"J Adolesc Health"},{"key":"2022031221304967600_B32","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.2337\/db07-1405","article-title":"Insulin mutation screening in 1,044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood","volume":"57","author":"Edghill","year":"2008","journal-title":"Diabetes"},{"key":"2022031221304967600_B33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11154-010-9151-3","article-title":"Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene","volume":"11","author":"St\u00f8y","year":"2010","journal-title":"Rev Endocr Metab Disord"},{"key":"2022031221304967600_B34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/adc.85.1.16","article-title":"The risk and outcome of cerebral oedema developing during diabetic ketoacidosis","volume":"85","author":"Edge","year":"2001","journal-title":"Arch Dis Child"},{"key":"2022031221304967600_B35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2337\/diacare.13.1.22","article-title":"Intracerebral crises during treatment of diabetic ketoacidosis","volume":"13","author":"Rosenbloom","year":"1990","journal-title":"Diabetes Care"},{"key":"2022031221304967600_B36","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/dme.13328","article-title":"Hyperglycaemia-related complications at the time of diagnosis can cause permanent neurological disability in children with neonatal diabetes","volume":"34","author":"Day","year":"2017","journal-title":"Diabet Med"},{"key":"2022031221304967600_B37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1037\/a0040455","article-title":"Neurocognitive consequences of diabetes","volume":"71","author":"Ryan","year":"2016","journal-title":"Am Psychol"},{"key":"2022031221304967600_B38","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fendo.2014.00161","article-title":"Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer\u2019s disease","volume":"5","author":"Bl\u00e1zquez","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2022031221304967600_B39","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed."},{"key":"2022031221304967600_B40","doi-asserted-by":"crossref","first-page":"e62646","DOI":"10.1371\/journal.pone.0062646","article-title":"Gain-of-function mutations in the K(ATP) channel (KCNJ11) impair coordinated hand-eye tracking","volume":"8","author":"McTaggart","year":"2013","journal-title":"PLoS One"},{"key":"2022031221304967600_B41","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1007\/s00125-006-0329-x","article-title":"Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene","volume":"49","author":"Tonini","year":"2006","journal-title":"Diabetologia"},{"key":"2022031221304967600_B42","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.2337\/diabetes.54.9.2503","article-title":"Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy","volume":"54","author":"Hattersley","year":"2005","journal-title":"Diabetes"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc18-1060","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/2\/215\/527338\/dc181060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/2\/215\/527338\/dc181060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:45:59Z","timestamp":1647128759000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/42\/2\/215\/30409\/Cognitive-Neurological-and-Behavioral-Features-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,10,30]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc18-1060","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]}}}